According to Operation Warp Speed Chief, Moncef Slaoui, the AstraZeneca and Oxford University vaccine may not receive the U.S. Food and Drug Administration’s Emergency Use Approval (EUA) until April, despite the UK’s approval yesterday (12/30). Questions surrounding efficacy of the vaccine as well as patient safety in older generations has raised concerns that has delayed the EUA of the vaccine. In addition, Slaoui suggested that the vaccine’s efficacy rate, which is 70% and well above the FDA’s requirements for a COVID-19 vaccine, would not be received well by U.S. regulators, since the Moderna as well as the Pfizer and BioNTech COVID-19 vaccines were both over 90%.

Read more here.

More on: